BUSINESS

• MSD, Kyorin to Copromote Nasonex Nasal Spray
  September 16, 2016

• Asahi Kasei Pharma Gets Japan Rights to Basilea’s Antifungal Agent
  September 16, 2016

• Lenvatinib Gets EU Nod for RCC: Eisai
  September 16, 2016

• Sawai, Tatsumi Kagaku Tie Up on Kipres Generics
  September 16, 2016

• Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
  September 14, 2016

• Takeda Returns Rights to MacroGenics’ RA Candidate MGD010
  September 14, 2016

• Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
  September 14, 2016

• “Regulatory Science Center” to Play Important Role to Establish Next-Generation Treatments: JPMA President
  September 13, 2016

• Novartis Paid 13.2 Billion Yen to Doctors, Medical Institutions in 2015
  September 13, 2016

• Nippon Shinyaku on Track to Achieve Targets in Midterm Plan with Sales of Selexipag Above Expectations: President
  September 12, 2016

• Sales of Ethical Drugs Down 6.4% in July: Crecon Report
  September 12, 2016

• Takeda Starts Global PIII for Dengue Vaccine
  September 9, 2016

• Aspen Japan Launches Paxil AG
  September 9, 2016

• Ono Files Kyprolis for Multiple Myeloma as Combo Therapy with Dexamethasone
  September 8, 2016

• Ono Rolls out Multiple Myeloma Treatment Kyprolis
  September 8, 2016

• Biogen Japan’s Hemophilia Spinoff to Be Up and Running in Early 2017
  September 8, 2016

• Sun Taps Mitsubishi Tanabe to Distribute Novartis’ 14 Established Brands
  September 7, 2016

• Psoriasis Treatment Apremilast Achieves Primary Endpoint in Japan PIIb Trial: Celgene
  September 7, 2016

• BIKEN, Kaketsuken to Develop Zika Virus Vaccines from Strain Isolated by Chiba Prefectural Institute of Public Health
  September 7, 2016

• Mitsubishi Tanabe Applies for Partial Change to Remicade Dosage to Shorten Administration Interval in Crohn’s Disease
  September 7, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 468
• 469
• 470
• 471
• 472
• 473
• 474
• 475
• 476
• …
• Next ›
• 最終 »